Fredun Pharmaceuticals Ltd approves H1 FY27 results and application to list and trade its shares on NSE
- Results cover the quarter and half-year ended 30 September 2026; financial figures were not included in the supplied material.
- NSE application is subject to applicable requirements.
- Statutory auditor’s limited review conclusions were unmodified, with no material misstatement reported.